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Background: Disagreement exists regarding the etiology of cessation of the observed clinical 
results with administration of reuptake inhibitors. Traditionally, when drug effects wane, it is 
known as tachyphylaxis. With reuptake inhibitors, the placebo effect is significantly greater than 
the drug effect in the treatment of depression and attention deficit hyperactivity disorder, leading 
some to assert that waning of drug effects is placebo relapse, not tachyphylaxis.
Methods: Two groups were retrospectively evaluated. Group 1 was composed of subjects with 
depression and Group 2 was composed of bariatric subjects treated with reuptake inhibitors 
for appetite suppression.
Results: In Group 1, 200 subjects with depression were treated with citalopram 20 mg per 
day. A total of 46.5% (n = 93) achieved relief of symptoms (Hamilton-D rating score # 7), 37 
(39.8%) of whom experienced recurrence of depression symptoms, at which point an amino 
acid precursor formula was started. Within 1–5 days, 97.3% (n = 36) experienced relief of 
depression symptoms. In Group 2, 220 subjects were treated with phentermine 30 mg in the 
morning and citalopram 20 mg at 4 pm. In this group, 90.0% (n = 198) achieved adequate 
appetite   suppression. The appetite suppression ceased in all 198 subjects within 4–48 days. 
Administration of an amino acid precursor formula restored appetite suppression in 98.5% 
(n = 195) of subjects within 1–5 days.
Conclusion: Reuptake inhibitors do not increase the total number of monoamine molecules in 
the central nervous system. Their mechanism of action facilitates redistribution of monoamines 
from one place to another. In the process, conditions are induced that facilitate depletion of 
monoamines. The “reuptake inhibitor monoamine depletion theory” of this paper offers a novel 
and unified explanation for the waning of response seen after a reuptake inhibitor is started, 
independent of a drug or placebo etiology.
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Introduction
Tricyclic antidepressants, nonspecific reuptake inhibitors, became available in 1956.1 
They dominated depression treatment until the first selective serotonin reuptake inhibitor 
(SSRI), fluoxetine, became available in 1988.1 The sympathomimetic anorectics, includ-
ing phentermine, diethylproprion, and phendimetrazine, induce weight loss through 
appetite suppression. Their mechanism of action is thought to include norepinephrine 
reuptake inhibition.2 As with the rest of the reuptake inhibitors, the mechanism of 
action of amphetamines is unknown. However, it is thought to be due to dopamine and 
norepinephrine reuptake inhibition, which induces appetite suppression. Amphetamines 
are also used in attention deficit hyperactivity disorder (ADHD).3 These classes of Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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reuptake inhibitors are also approved for other applications. 
  Fluvoxamine, an SSRI, is approved only for the treatment of 
obsessive-compulsive   disorder and social anxiety syndrome.4 
Bupropion hydrochloride, a dopamine and norepinephrine 
reuptake inhibitor, is indicated for smoking discontinuation.5
Reuptake inhibitors share the property of tolerance, 
that is waning of the drug’s effects. In other classes of drugs 
this effect is known as tachyphylaxis.   Tachyphylaxis is for-
mally defined as a “diminished response to later increments 
in a sequence of applications of a physiologically active 
substance”6 (ie, the drug stops working and its clinical effects 
are no longer observed). The concept of reuptake inhibitor 
tachyphylaxis is controversial. Double-blind, placebo-con-
trolled studies reveal that in depression and ADHD treatment, 
the placebo response is greater than the drug effect in relief 
of symptoms.7,8 This leads to the argument that discontinu-
ation of a drug’s clinical effects predominantly represents a 
placebo relapse rather than drug tachyphylaxis.9,10
This paper presents the novel reuptake inhibitor mono-
amine depletion theory, which explains why symptoms that 
are controlled at the start of treatment return, irrespective 
of the cause of initial relief (placebo relapse or drug tac-
hyphylaxis). Under this novel theory, a relative nutritional 
deficiency occurs, a situation that can only be managed with 
administration of proper levels of nutrients.
The following scientific facts exist. The monoamines – 
serotonin, dopamine, norepinephrine, and epinephrine – do 
not cross the blood–brain barrier. There are a finite number of 
monoamine neurotransmitter molecules in the central nervous 
system (CNS). Reuptake inhibitor drugs do not increase the 
total number of these centrally acting monoamine molecules 
in the CNS. The only way to increase the total number of 
monoamine molecules in this finite CNS universe is through 
a nutritional approach with administration of properly bal-
anced serotonin and dopamine amino acid precursors. These 
precursors cross the blood–brain barrier and are synthesized 
in the CNS into new monoamine molecules.8,9,11–16
Methods and materials
Serotonin, dopamine, norepinephrine, and epinephrine are 
herein referred to as “monoamines”. A comprehensive search 
of the literature was performed, specifically focusing on 
depletion of monoamines by reuptake inhibitors, reuptake 
inhibitor tachyphylaxis, and placebo relapse of depression 
and ADHD symptoms. 
Two pilot study groups were identified. Group 1 was 
composed of 200 subjects taking the SSRI citalopram for 
depression, which was screened initially with the Diagnostic 
and Statistical Manual of Mental Disorders, Fourth Edition 
(DSM-IV) criteria17, then tracked with the Hamilton-D rating 
scale for depression. The number of Group 1 subjects who 
initially achieved relief of depression symptoms (Hamilton-D 
≤ 7) was n = 93. Subjects who did not initially achieve relief of 
depression symptoms on 20 mg of citalopram each morning 
(Hamilton-D . 7) were excluded from the study. The next 
criterion for inclusion was the return of depression symptoms 
(n = 37) while taking the prescribed reuptake inhibitor drug.
Group 2 was composed of 220 patients taking a combina-
tion of citalopram and phentermine for appetite suppression 
during bariatric treatment (see Table 2). Since tools do not exist 
for evaluating drug-induced appetite suppression, the following 
novel questions were used; a positive answer to any question 
indicated inadequate appetite suppression. “Since your last 
office visit have you: been inappropriately snacking on food, 
been inappropriately nibbling on food, eaten more than your 
calorie prescription, or needed to use willpower to stay away 
from food in order to keep on your diet?” The number of Group 
2 subjects who achieved initial control of appetite was n = 
198. Subjects who did not initially achieve adequate appetite 
control were excluded from the study. The next criterion for 
inclusion was the loss of appetite suppression (n = 198) while 
taking the prescribed reuptake inhibitor drugs.
Subjects were instructed to immediately report the return of 
depression symptoms or loss of appetite control. Subjects were 
then continued on the drug(s) and started on monoamine amino 
acid precursors and cofactors in divided doses at the following 
daily dosing values: L-cysteine 4500 mg, L-tyrosine 3000 mg, 
vitamin C 1000 mg, L-lysine 500 mg, 5-hydroxytryptophan 
(5-HTP) 300 mg, calcium citrate 220 mg, vitamin B6 75 mg, 
folate 400 µg, and selenium 400 µg.
A full discussion of the scientific basis for each of these 
amino acid and cofactor nutrients is covered in the authors’ previ-
ous writings.8,9,11–16,20–22 A brief overview is as follows. L-tyrosine 
and 5-HTP are dopamine and serotonin precursors, respectively. 
Vitamin C, vitamin B6, and calcium citrate are cofactors required 
in the synthesis of serotonin and/or dopamine. L-cysteine is 
administered to compensate for L-tyrosine-induced depletion of 
sulfur amino acids. Folate is required for optimal sulfur amino 
acid synthesis. Selenium is given in response to cysteine’s abil-
ity to concentrate methylmercury in the CNS. L-lysine prevents 
loose hair follicles during bariatric treatment.
Results
group 1: depression
A group of 200 patients who were positively diagnosed with 
depression on DSM-IV depression criteria screening and had Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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a Hamilton-D depression score . 7 (see row 1, Table 1) were 
identified. All were started on citalopram 20 mg per day in 
the morning. Two weeks after the initiation of treatment with 
citalopram 20 mg, 93 subjects were diagnosed with remission 
of depression (Hamilton-D # 7; row 2, Table 1). The remission 
group continued citalopram 20 mg each morning. All were 
instructed to immediately report if depression returned. They 
were then followed in clinic every 2–4 weeks. In the 18 months 
after symptom control had been achieved, 37 subjects experi-
enced return of depression (Hamilton-D . 7; row 3, Table 1). 
They were re-evaluated using the Hamilton-D depression scale 
within 14 days of return of symptoms then started on the amino 
acid formula discussed in the Materials and methods section. 
On this amino acid formula, 36 of the 37 subjects reported 
relief of symptoms, with a mean time of 1.9 days and a range 
of 1 to 5 days (see Tables 3 and 4). Follow-up 6 months later 
revealed no return of depression symptoms in those subjects 
taking the amino acid formula.
group 2: appetite suppression
Group 2, comprising 220 subjects, was started on 15 mg of 
phentermine in the morning with 20 mg of citalopram at 4 
pm for control of   appetite in a bariatric medicine program. 
One week later, independent of the appetite control in place, 
all were increased to 30 mg of phentermine in the morning 
with 20 mg of citalopram at 4 pm. One week later, 198 sub-
jects were found to have adequate appetite suppression and 
were then followed with weekly visits to monitor appetite 
suppression. Novel questioning (as covered in the Methods 
and materials section) revealed inadequate appetite control in 
all subjects within 4–48 days, at which point the drugs were 
continued and the amino acid formula outlined in the Meth-
ods and materials section was started. Within 1–5 days, 195 
of the 198 subjects (98.5%) experienced return of adequate 
appetite suppression.
A consistent phenomenon occurred with Group 2 
  participants. When the amino acid precursor formula was 
added, each participant in Group 2 was able to retrospectively 
identify the exact day that appetite suppression was restored. 
This observation is consistent with a novel and sharply 
demarcated monoamine threshold. When monoamine levels 
were above the threshold, appetite suppression was observed. 
When monoamine levels were below the threshold, appetite 
suppression effects were not observed.
Discussion
The following definitions are put forth. Two basic types of 
nutritional deficiencies may occur: a “deficiency of nutrient 
Table 1 Hamilton-D rating scale scores for group 1 (depression, n = 37)
n Mean Hamilton  
score
Hamilton score  
ranges
Standard deviation  
of Hamilton Score
Demographics 
Female
Demographics 
Male
n (%)  
Age range (years) 
Mean age (years)  
SD (years)
n (%)  
Age range (years)   
Mean age (years)  
SD (years)
Pretreatment score (.7) 200 10 8–21 3.39 n = 126 (63.0%)  
18.1–74.2 
51.9 
10.5
n = 34 (37.0%)  
25.4–81.6 
54.1 
11.5
Scores two weeks after  
starting drug (#7)
93 5 1–7 1.76 n = 60 (64.5%)  
22.3–74.2 
52.8 
10.2
n = 33 (35.5%)  
25.4–74.5 
53.2  
11.1
Score when effects  
no longer observed
37 12 7–23 3.61 n = 24 (64.9%)  
23.4–68.2 
50.7 
9.1
n = 13 (35.1%)  
25.4–67.4 
51.1  
9.8
Score one week after  
starting amino acids
36 4 0–7 1.99 n = 23 (63.9%)  
23.4–68.2 
50.6 
9.1
n = 13 (36.1%)  
25.4–67.4 
51.1  
9.8
Notes: row 1: Hamilton-D score prior to starting citalopram 20 mg in the morning. row 2: Hamilton-D score after relief of depression achieved on citalopram 20 mg per 
day. row 3: Hamilton-D score when initial relief of symptoms after starting citalopram was no longer observed. row 4: Hamilton-D score one week after the amino acid and 
cofactor formulation was started in combination with citalopram 20 mg.
Abbreviation: SD, standard deviation.Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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intake” and a “relative nutritional deficiency.” Relative nutri-
tional deficiencies arise from changes in system status or from 
system needs that give rise to increased nutrient dosing needs 
that are beyond the limits of dietary modification.
The theoretical model of monoamine 
depletion
The central theory of this paper rests on the following foun-
dation: reuptake inhibitors facilitate conditions that deplete 
monoamines, reuptake inhibitors will not function if mono-
amine depletion is significant enough, and when significant 
monoamine depletion occurs, the placebo effect and/or drug 
effect may no longer be observed.
The monoamines exist in one of two states. (1) The endog-
enous state is the normal day-to-day state found when no amino 
acid precursors are administered. In this state, monoamine 
levels are at or below the normal values of the reference range. 
(2) The competitive inhibition state is observed when significant 
amounts of serotonin and dopamine amino acid precursors are 
simultaneously administered. In this state, monoamine levels 
are higher than are normally found in the system.8,11,13–16
The mechanism of action for reuptake inhibitors is only 
theoretical; objective measurements do not exist. A debate 
exists over drug tachyphylaxis versus placebo relapse when 
there is a return of symptoms of depression or ADHD after 
being controlled at the start of the drug. Relapse supporters 
claim their argument makes room for recurrence of symptoms 
in the presence of a large placebo effect combined with a 
small drug effect.9,10
It is postulated that the following novel reuptake inhibitor 
monoamine depletion theory is a viable explanation, espe-
cially in light of the amino acid observations summarized 
in Tables 1, 3, and 4 plus the differentiation of synaptic and 
postsynaptic electrical dysfunction. The reuptake inhibitor 
monoamine depletion theory states that reuptake inhibitors 
deplete the monoamines serotonin, dopamine, norepineph-
rine, and epinephrine in all subjects not ingesting adequate 
amounts of balanced nutrients; when depletion is significant 
enough, a point is reached where the effects of the drug and/
or the placebo effect are no longer observed.
The uniform and consistent response observed with 
low-dose amino acid dosing values, which uniformly places 
all subjects in the lower end of the competitive inhibition 
state, supports the reuptake inhibitor monoamine depletion 
theory.
The reported numbers (n) in rows 3 and 4 of Table 1 are 
higher than expected based on expected drug response alone, 
meaning that these subjects are a mix of placebo respond-
ers and drug responders. Note that >97% of this group 
responded to the administration of amino acid precursors. 
It is therefore concluded that this is a synaptic phenomenon 
related to monoamine depletion by reuptake inhibitors, 
which is the primary cause of placebo relapse and drug 
tachyphylaxis.
Table 3 group 1 achieved relief of depression symptoms after 
starting citalopram then experienced return of symptoms leading 
to the listed observation. group 2 achieved appetite suppression 
then experienced a lapse in the control of hunger leading to the 
listed observations
n Group 1 
37
Group 2 
198
Mean (days to discontinuation  
of effects after starting the drug[s])
164 22
range (days to discontinuation  
of effects after starting the drug)
34–490 4–48
Standard deviation 107.5 9.1
Table 2 group 2 demographics of bariatric group by gender at start 
of treatment and at evaluation of quality of appetite suppression
Demographics  
Female
Demographics 
Male
n (%)  
Mean age (years)  
Age range (years)  
Age SD (years)
n (%)  
Mean age (years)  
Age range (years)   
Age SD (years)
220 entering study 173 (78.6%) 
46.1  
18.1–69.6 
10.1
47 (21.4%) 
49.2 
19.3–63.5 
9.4
198 with adequate  
appetite suppression  
studied
157 (79.3%) 
46.1  
18.8–68.2 
9.7
63 (20.7%) 
49.2 
19.3–63.5 
9.3
Abbreviation: SD, standard deviation.
Table 4 group 1 subjects achieved relief of depression symptoms 
after starting citalopram and then experienced a return of symptoms. 
The  amino  acid  precursor  formula  was  then  administered  in 
combination  with  citalopram,  and  the  listed  study  parameters 
were observed. group 2 subjects achieved appetite suppression 
after starting citalopram and phentermine in combination, then 
experienced  a  return  of  appetite.  The  amino  acid  precursor 
formula was then administered in combination with citalopram and 
phentermine and the listed parameters were observed
n Group 1 
37
Group 2 
198
effects restored (n, [%]) 36 (97.3%) 195 (98.5%)
Mean time to restore effects (days) 1.6 days 1.9 days
range (days) 1–3 1–5
Standard deviation 0.26 days 0.39 daysDrug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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It is proposed that monoamine depletion is the correct 
description of the event that occurs when drug or placebo 
effects observed after the start of a reuptake inhibitor are no 
longer present in the endogenous state. With monoamine 
depletion, the synaptic monoamine levels decrease due to 
a relative nutritional deficiency that is beyond the capa-
bilities of dietary modification to correct. The effects of 
placebo and/or drug efficacy will not be available if there 
are not enough monoamines in the system. With significant 
monoamine depletion by reuptake inhibitors, there may be 
a return of the original disease symptoms or new onset of 
disease symptoms. 
relapse versus tachyphylaxis
Some argue that, with reuptake inhibitor treatment of depres-
sion and ADHD, the placebo effect is the dominant force 
facilitating the clinical response; therefore, the appropriate 
term when symptoms return after a reuptake inhibitor response 
is observed is “relapse,” rather than drug tachyphylaxis.9,10 The 
placebo effect in depression ranges from 30% to 45%, and drug 
efficacy over placebo ranges from 7% to 13%.7   Double-blind, 
placebo-controlled depression studies reveal that the efficacy 
of placebo is three to six times greater than that of reuptake 
inhibitors. In these studies, the drug effect is so small that 
87%–93% treated with a reuptake inhibitor can expect relief 
of symptoms no greater than that provided by placebo.7
Double-blind, placebo-controlled ADHD studies of atom-
oxetine indicate placebo efficacy in the range of 28%–40%, 
with drug efficacy 12%–26% greater than placebo. Studies 
support the conclusion that 74%–88% of ADHD patients 
treated with atomoxetine can expect relief of symptoms no 
greater than that provided by placebo.8
Monoamine depletion
The primary theory expounded by this paper is that when 
symptomatic relief related to a drug or placebo wanes, it 
is primarily due to drug-induced monoamine depletion. 
Monoamine depletion studies done in conjunction with 
amino acid precursor utilization have demonstrated that a 
decrease in monoamine concentrations is associated with 
the waning or outright discontinuation of the drug-induced 
effects.18,19
Serotonin and dopamine are synthesized from the amino 
acid precursors 5-hydroxytryptophan (5-HTP) and L-3,4-
dihydroxyphenylalanine (L-dopa), respectively. L-dopa is 
synthesized from L-tyrosine and 5-HTP is synthesized from 
L-tryptophan. Dopamine is the precursor of norepinephrine, 
which, in turn, is the precursor of epinephrine.7,8,11–16,20–22
Monoamines do not cross the blood–brain barrier. When 
monoamine depletion of the CNS occurs, the only way to 
address this relative nutritional deficiency and increase the 
total number of monoamine molecules in the CNS is through 
nutritional means, with the simultaneous administration of 
properly balanced serotonin and dopamine amino acid precur-
sors with cofactors. These precursors cross the blood–brain 
barrier and are then synthesized, freely or with biochemical 
feedback regulation depending on the amino acid, into new 
monoamines, which, when levels are high enough, restore 
the efficacy of the drug or placebo effect.8,9,11–16,21
Depletion of platelet monoamines: 
peripheral evidence
Platelets contain 90% of the releasable serotonin stores. 
Reuptake inhibitor studies demonstrate that 90% of platelet 
serotonin is depleted in about 3 weeks. Over 80% of the total 
releasable serotonin is depleted within 3 weeks after starting 
reuptake inhibitors. The mechanism of platelet depletion is 
attributed to blocking reuptake transport of serotonin into 
platelets while allowing for transport out of the platelets. 
Once outside the platelets, the serotonin is exposed to the 
monoamine oxidase enzymes that affect metabolism at a 
higher rate leading to depletion. This is the same mechanism 
of action observed with monoamine transport in and out of 
the presynaptic neurons of the CNS, as illustrated in Figures 
1–3.23–30
Depletion in cnS
Do reuptake inhibitors facilitate CNS monoamine deple-
tion? In excess of 80% of the releasable stores of serotonin 
are depleted after 3 weeks of reuptake inhibitor treatment. 
Figure 1 inadequate levels of neurotransmitters in the synapse are associated with 
compromised electrical flow in the postsynaptic neurons, leading to suboptimal 
regulation of function and/or development of symptoms.34Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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There is disagreement over the depletion of monoamines 
by reuptake inhibitors in the CNS. Supporters of reuptake 
inhibitors assert that there is no evidence of CNS monoamine 
depletion by these drugs. Those in opposition, including the 
National Institute on Drug Abuse, claim that reuptake inhibi-
tors deplete CNS monoamines.23–30
One paper bridges the gap, its authors initially recognizing 
articles claiming reuptake inhibitors do not deplete mono-
amines in the CNS. The article then identifies pathological 
and morphological changes that occur with drug depletion 
and goes on to explain that these same changes are seen 
with reuptake inhibitor administration. These morphological 
changes are found with all reuptake inhibitors reviewed. A 
spectrum of depletion is concluded.31
Differentiating synaptic and postsynaptic 
dysfunction
While the focus of monoamine reuptake inhibitor depletion is 
on synaptic monoamine levels, there are other causes of electri-
cal dysfunction, such as receptor desensitization and receptor 
down regulation. While these may be valid topics, they do not 
apply here. The phenomenon observed here is clearly electrical 
dysfunction of synaptic origin, whereas receptor desensitiza-
tion, receptor down regulation, bundle damage, and so forth, are 
all postsynaptic processes linked to the postsynaptic neurons. 
As discussed in the authors’ previous work, there are unique 
observations that define synaptic electrical dysfunction versus 
postsynaptic-driven electrical dysfunction. Considerations are 
as follows. Correcting monoamine depletion-associated syn-
aptic electrical dysfunction in the endogenous state involves 
addressing the problem nutritionally to increase monoamine 
concentrations from low to normal.7,8,11–16,20–22 Correcting 
dysfunction associated with postsynaptic structures requires 
nutritionally establishing monoamine levels in the competitive 
inhibition state, where monoamine levels are higher than those 
found in the endogenous (normal) state.7,8,11–16,20–22 Differentia-
tion between synaptic and postsynaptic electrical dysfunction 
is possible by observing the clinical response to group admin-
istration of nutrients (amino acid precursors with cofactors), 
shown in Table 5.7,8,11–16,20–22
When dysfunction is due to low or inadequate synap-
tic monoamine levels associated with depletion, return-
ing monoamine levels to the normal reference range of 
the population in the endogenous state will correct the 
problem.7,8,11–16,20–22 In Group 1 and Group 2, over 97% of 
subjects who experienced waning of initial drug effects were 
suffering from monoamine electrical dysfunction secondary 
to developing a relative nutritional dysfunction. These sub-
jects were placed on the lowest (starting) amino acid dosing 
value required to induce the competitive inhibition state 
leading to a positive and uniform response. As discussed 
more thoroughly below, when synaptic monoamine electri-
cal dysfunction is present, returning monoamine levels to 
the normal range for the population or immediately above 
normal restores the initial effects observed with administra-
tion of the drug.7,8,11–16,20–22
When the electrical dysfunction is due to postsynaptic 
neuron structural impairment, the serotonin and dopamine 
amino acid precursor dosing values required to fully 
Figure  2  With  administration  of  reuptake  inhibitors,  blockage  of  monoamine 
transport  back  into  the  presynaptic  neurons  leads  to  a  net  redistribution  of 
neurotransmitter molecules from the presynaptic neuron to the synapse. increased 
levels of synaptic monoamines lead to increased flow of electricity which causes 
adequate regulation of function and/or relief of symptoms.34
Figure 3 When the monoamines are in the vesicles of the presynaptic neuron they 
are not exposed to the enzymes that catalyze metabolism (monoamine oxidase and 
catechol-0-methyl transferase). They are safe from metabolism. When they relocate 
outside the vesicles presynaptic neuron, they are exposed at a greater frequency to 
these enzymes. reuptake inhibitors create a mass migration of monoamines causing 
increased metabolic enzyme activity and metabolism of monoamines. This leads to 
monoamine  depletion  if  significant  amounts  of  balanced  serotonin  and  dopamine 
precursors are not coadministered with the reuptake inhibitor.34Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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compensate for the dysfunction are not uniform and are 
highly individualized.7,8,11–16,20–22
As the authors have previously discussed, the following 
considerations exist while documenting the novel effects 
of nutritional dosing value alterations on organic cation 
transporter (OCT) function status in the competitive inhibition 
state. The serotonin and dopamine precursor dosing values 
needed to compensate for postsynaptic monoamine–associ-
ated electrical dysfunction in the competitive inhibition state 
range from very low to very high. When optimal amino acid 
precursor dopamine values in the competitive inhibition state 
are achieved, as evidenced by properly balanced OCT sero-
tonin and dopamine transport, the serotonin amino acid dosing 
value is independent of the dopamine amino acid dosing 
value. In addition, if OCT functional status interpretation 
considerations are not affected, the dosing values of serotonin 
and dopamine amino acid precursors needed to effectively 
optimize and restore postsynaptic monoamine–related electri-
cal function have been demonstrated to be random relative to 
serotonin and dopamine assay levels. 7,8,11-16,20-22
In the case of reuptake inhibitor placebo relapse and/or 
reuptake inhibitor tachyphylaxis, the amino acid dosing 
values required to correct the relative nutritional deficiency 
are   relatively low, uniform, and constant. This is consistent 
with synaptic monoamine electrical dysfunction in endog-
enous state. It is not consistent with the highly individual-
ized group-dosing value needs observed in the competitive 
inhibition state, which is linked to postsynaptic monoamine 
electrical dysfunction (see Table 5).7,8,11–16,20–22
neurotransmitter depletion  
by reuptake inhibitors
It is known that the reuptake inhibitor methamphetamine 
depletes dopamine,32 which facilitates the neurotoxicity.8 
SSRIs are known to decrease serotonin synthesis.33 The 
nonspecific reuptake inhibitor amitriptyline (a tricyclic 
antidepressant) is known to deplete norepinephrine.34 The 
National Institute on Drug Abuse has posted figures (Fig-
ures 1–3) on its website, which are in the public domain. 
These figures illustrate how reuptake inhibitors deplete 
monoamines.35
Other depletion-related problems
Monoamine depletion may explain other problems associated 
with reuptake inhibitors. The US Food and Drug Adminis-
tration requires that reuptake inhibitors display a black box 
warning regarding the risk of suicidal ideation while taking 
these drugs.4,5 It is postulated that this increased suicide risk 
may be associated with monoamine depletion by reuptake 
inhibitors.
Reuptake inhibitor discontinuation syndrome is an 
  exacerbation of symptoms or new onset of symptoms that 
occurs when attempts are made to stop a reuptake inhibitor. 
The patients typically, do not like the way they feel when 
attempts to stop the drug are made; consequently they are 
trapped into taking a drug that provides little relief of symp-
toms because they feel worse without the drug.37 It is postu-
lated that reuptake inhibitor–induced monoamine depletion 
plays a role in this phenomenon.
Customarily, when the clinical effect of a reuptake inhibi-
tor stops, the response is to increase the daily dosing value 
of the drug, start a second reuptake inhibitor, or stop the first 
drug then substitute a second drug. It is postulated that all of 
these actions further facilitate monoamine depletion.
general observations
It is postulated that if the reuptake inhibitor drug was intro-
duced into an environment in which synaptic monoamine 
homeostasis always existed, with no postsynaptic issues 
arising, the drug would theoretically continue to function 
indefinitely. However, this is not the case. It is well known 
that these drugs, in the endogenous state, are associated with 
return of symptoms, discontinuation syndrome, placebo 
relapse, drug tachyphylaxis, suicidal ideation, reuptake 
inhibitor discontinuation syndrome, induced relative nutri-
tional deficiency, and a number of other problems. Reuptake 
inhibitor monoamine depletion theory is the only model that 
unifies and explains the phenomena described in this paper 
Table 5 Observed differences between synaptic and postsynaptic 
electrical dysfunction
Synaptic 
dysfunction
Postsynaptic  
dysfunction
electrical dysfunction  
is corrected with monoamines  
in which state?
endogenous  
state
competitive  
inhibition state
returning monoamines  
to normal levels
Will restore  
function
Will not  
restore function
Uniform response to a  
low-dose competitive inhibition  
amino acid dosing value
Yes no
individualized amino acid  
dosing value needed
no Yes
requires adjusting amino acid  
dosing values for  
optimal group results
no Yes
need to obtain organic  
cation transporter functional  
status determination  
for optimal results
no YesDrug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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when the nutritional responses of Group 1 and Group 2 are 
considered.
Reuptake inhibitors are a drug class that offer only 7%–13% 
of patients relief of depression symptoms that is greater than 
that provided by placebo.7 They make the disease cause worse 
by depleting the centrally acting monoamine neurotransmitters 
in all patients who do not ingest adequate amounts of serotonin 
and dopamine amino acid precursors, which leads to a relative 
nutritional deficiency. They also expose 100% of patients to 
drug side effects and the economic costs of the drugs.
Worldwide annual sales of antidepressants coming off 
patent between 2011 and 2016 is placed in excess of US$255 
billion.37 If 87% of patients taking these drugs had no hope 
of achieving relief of depression symptoms greater than 
that provided by placebo, this would mean that US$221.9 
billion is being spent annually for treatment that is no more 
effective than a sugar pill. This number increases when the 
cost of drugs already off patent are included.
The Internet is replete with claims that 5-HTP should not 
be administered with reuptake inhibitors due to concerns of 
serotonin syndrome. The authors firmly assert that this is not 
correct. There are no reported cases of serotonin syndrome 
resulting from concurrent use of 5-HTP with reuptake inhibi-
tors in the literature. Since 1997, the authors have amassed 
over 2 million patient-days of treatment experience using 
5-HTP with reuptake inhibitors from over 1000 medical clin-
ics, with not one case of serotonin syndrome documented.
Conclusion
SSRIs used in the treatment of depression and ADHD are 
associated with low efficacy and high placebo response. This 
leads to controversy in defining the cause for the discontinu-
ation of symptomatic relief observed after starting a reuptake 
inhibitor. Prior to this paper, the question was, “When depres-
sion symptoms return, is it due to drug tachyphylaxis or a 
placebo relapse?” This paper puts forth the unified concept 
of the reuptake inhibitor monoamine depletion theory.
Relative nutritional deficiency can exist when dietary 
intake is normal and changes to the system occur that can-
not be met through dietary modification alone. Increased 
metabolism and inadequate synthesis of monoamines create 
an environment where the relative nutritional deficiency asso-
ciated with reuptake inhibitor treatment evolves. When this 
happens, administration of serotonin and dopamine amino 
acid   precursors is the only course available to compensate for 
CNS monoamine depletion by reuptake inhibitors.
The ability of reuptake inhibitors to induce a relative nutri-
tional deficiency leading secondarily to depletion of monoamines 
has been overlooked and is of serious concern. When monoamine 
depletion is extensive enough, placebo relapse occurs, drug 
tachyphylaxis occurs, symptoms of disease return, new onset of 
disease symptoms may occur, increased incidence of suicidal 
ideation may be facilitated, and reuptake inhibitor discontinua-
tion syndrome may be observed, regardless of the initial cause of 
symptomatic relief (placebo effect versus drug effect).
Reuptake inhibitors do not increase the total number 
of monoamines in the CNS. Their mechanism of action 
facilitates redistribution of monoamines from one place to 
another, which, in turn, sets up conditions that favor deple-
tion of monoamines if proper levels of nutrients are not 
administered.
Physicians currently prescribe reuptake inhibitor drugs 
that are only 7%–13% more effective than placebo in treating 
depression7 and only 12%–26% more effective than placebo 
in treating ADHD.8 Reuptake inhibitors are known to further 
deplete the very monoamines whose inadequate synaptic 
levels are implicated in the etiology of numerous diseases 
and conditions. This makes the cause of the disease (ie, 
inadequate monoamine levels) worse. Monoamine depletion 
is a relative nutritional deficiency that cannot be managed 
adequately by dietary modification.
In the treatment of depression, 87%–93% of patients 
taking these drugs cannot expect relief of symptoms that 
is greater than that provided by placebo.7 In the treatment 
of ADHD, 74%–88% of patients cannot expect relief of 
symptoms greater than that provided by placebo.8 How-
ever, 100% of patients are subjected to the side effects, 
the cost of the drugs, development of a relative nutritional 
deficiency, and depletion of   monoamines by reuptake 
inhibitors if simultaneous administration of properly 
balanced serotonin and dopamine amino acid precursors 
does not occur.
Reuptake inhibitors are the only class of drugs that the 
authors are aware of that make the cause of the disease 
(inadequate levels of monoamines) that is being treated 
worse. With experience comes insight: the manufacturer of 
citalopram reported that one of the authors of this article 
was the largest private practice prescriber of this drug in 
1999, the first full year after the drug became available in 
the USA. This paper attempts to raise the level of awareness, 
understanding, stimulate further studies, and facilitate dialog 
regarding monoamine depletion by reuptake inhibitors.
Disclosure
MH discloses ownership of NeuroResearch Clinics Inc, Cape 
Coral, FL. TU discloses laboratory directorship of DBS Labs, Drug, Healthcare and Patient Safety
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/drug-healthcare-and-patient-safety-journal
Drug, Healthcare and Patient Safety is an international, peer-reviewed 
open-access journal exploring patient safety issues in the healthcare 
continuum from diagnostic and screening interventions through to treat-
ment, drug therapy and surgery. The journal is characterized by the rapid 
reporting of reviews, original research, clinical, epidemiological and 
post-marketing surveillance studies, risk management, health literacy 
and educational programs across all areas of healthcare delivery. The 
manuscript management system is completely online and includes a very 
quick and fair peer-review system. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
77
Monoamine depletion by reuptake inhibitors
Duluth, MN. AS declares no conflicts of interest in relation 
to this paper.
References
  1.  Frank R, Glied S. Better but Now Well: Mental Health Policy in the 
United States since 1950. Baltimore, MD: Johns Hopkins University 
Press; 2006.
  2.  Mantzoros C. Nutrition and Metabolism: Underlying Mechanisms and 
Clinical Consequences. Totowa, NJ: Humana Press; 2009.
  3.  Dextroamphetamine and amphetamine (CII) prescribing information. 
Available from: http://www.accessdata.fda.gov/drugsatfda_docs/
label/2007/011522s040 lbl.pdf. Accessed July 30, 2011.
  4.  Fluvoxetine prescribing information. Available from: http://www.
luvoxcr.com/LUVOX-CR-PI.pdf. Accessed July 30, 2011.
  5.  Bupropion prescribing information. Available from: http://us.gsk.com/
products/assets/us_zyban.pdf. Accessed July 30, 2011.
  6.  Merriam-Webster online dictionary http://www.merriam-webster.com/ 
medical/tachyphylaxis?show = 0&t = 1312033095. Accessed   
July 30, 2011.
  7.  Hinz M. Depression. In: Kohlstadt I, editor. Food and Nutrients in 
Disease Management. Boca Raton, FL: CRC Press; 2009.
  8.  Hinz M, Stein A, Uncini T. Treatment of attention deficit hyperac-
tivity disorder with monoamine amino acid precursors and organic 
cation transporter assay interpretation. Neuropsychiatr Dis Treat. 
2011;7:31–38.
  9.  McGrath P, Stewart J, Quitkin F. Predictors of relapse in a prospective 
study of fluoxetine treatment of major depression. Am J Psychiatry. 
2006;163:1542–1548.
  10.  Michelson D, Buitelaar J, Danckaerts M. Relapse prevention in pediatric 
patients with ADHD treated with atomoxetine: a randomized, double 
blind, placebo controlled study. J Am Acad Child Adolesc Psychiatry. 
2004;43:896–904.
  11.  Hinz M, Stein A, Uncini T. The dual-gate lumen model of renal mono-
amine transport Neuropsychiatr Dis Treat. 2010;6:387–392.
  12.  Hinz M, Stein A, Trachte G, Uncini T. Neurotransmitter testing of the 
urine: A comprehensive analysis. Open Access Journal of Urology. 
2010;2:177–183.
  13.  Hinz M, Stein A, Uncini T. Urinary neurotransmitter testing: consider-
ations of spot baseline norepinephrine and epinephrine. Open Access 
Journal of Urology. 2011;3:19–24.
  14.  Hinz M, Stein A, Uncini T. Amino acid management of Parkinson’s 
disease: A case study. Int J Gen Med. 2011;4:1–10.
  15.  Hinz M, Stein A, Uncini T. Validity of urinary monoamine assay sales 
under the “spot baseline urinary neurotransmitter testing marketing 
model”. Int J Nephrol Renovasc Dis. 2011;4:101–113.
  16.  Hinz M, Stein A, Uncini T. APRESS: apical regulatory super sys-
tem, serotonin, and dopamine interaction. Neuropsychiatr Dis Treat. 
2011;7:457–463.
  17.  Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, 
1994 (American Psychiatric Association) p. 372
  18.  Delgado P, Miller H, Salomon R, et al. Tryptophan-depletion challenge 
in depressed patients treated with desipramine or fluoxetine: implica-
tions for the role of serotonin in the mechanism of antidepressant action. 
Biol Psychiatry. 1999;46:212–220.
  19.  Page M, Detke M, Dalvi A, et al. Serotonergic mediation of the effects 
of fluoxetine, but not desipramine, in the rat forced swimming test. 
Psychopharmacology. 1999;147:162–167.
  20.  Trachte G, Uncini T, Hinz M. Both stimulatory and inhibitory effects of 
dietary 5-hydroxytryptophan and tyrosine are found on urinary excretion 
of serotonin and dopamine in a large human population. Neuropsychiatr 
Dis Treat. 2009;5:227–235.
  21.  Stein A, Hinz M, Uncini T. Amino acid responsive Crohn’s disease, a 
case study. Clin Exp Gastroenterol. 2010:3:171–177.
  22.  Hinz M, Stein A, Uncini T. A pilot study differentiating recurrent major 
depression from bipolar disorder cycling on the depressive pole. Neu-
ropsychiatr Dis Treat. 2010;6:741–747.
  23.  Alvarez J, Sanceaume M, Advenier C, et al. Differential changes in 
brain and platelet 5-HT concentrations after steady-state achievement 
and repeated administration of antidepressant drugs in mice. Eur Neu-
ropsychopharmacol. 1999;10:31–36.
  24.  Dalton S, Johansen C, Mellemkjar L, et al. Use of selective serotonin 
reuptake inhibitors and risk of upper gastrointestinal tract bleeding. 
Arch Intern Med. 2003;163:59–64.
  25.  Wagner A, Montero D, Martensson B, et al. Effects of fluoxetine treat-
ment of platelet 3H-imipramine binding, 5-HT uptake and 5-HT content 
in major depressive disorder. J Affect Disord. 1990;20:101–113.
  26.  Yuan Y, Tsoi K, Hunt R. Selective serotonin reuptake inhibitors and 
risk of upper GI bleeding: Confusion or confounding? Am J Med. 
2006;119:719–727.
  27.  Meier C, Schlienger R, Jick H. Use of selective serotonin reuptake 
inhibitors and risk of developing first-time acute myocardial infarction. 
Br J Clin Pharmacol. 2001;52:179–184.
  28.  Fuller R, Wong D. Serotonin uptake and serotonin uptake inhibition. 
Ann N Y Acad Sci. 1990;600:68–78.
  29.  de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S. Intracranial haem-
orrhage and use of selective serotonin reuptake inhibitors. Br J Clin 
Pharmacol. 2000;50:43–47.
  30.  Layton D, Clark D, Pearce D, Shakir SA. Is there an association between 
reuptake inhibitors and the risk of abnormal bleeding? Eur J Clin 
Pharmacol. 2001;57:167–176.
  31.  Kalia M, O’Callaghan J, Miller D, et al. Comparative study of fluox-
etine, sibutramine, sertraline and dexfenfluramine on the morphology 
of serotonergic nerve terminals using serotonin immunohistochemistry. 
Brain Res. 2000;858:92–105.
  32.  Cooney C, Wise C, Poirier LA, Ali SF. Methamphetamine treatment 
affects blood and liver S-adenosylmethionine (SAM) in mice: cor-
relation with dopamine depletion in the striatum. Ann NY Acad Sci. 
1998;844:191–200.
  33.  Stenfors C, Yu H, Ross S. Pharmacological characterisation of the 
decrease in 5-HT synthesis in the mouse brain evoked by the selec-
tive serotonin re-uptake inhibitor citalopram. Arch Pharmacol. 
2001;363:222–232.
  34.  Galun E, Flugelman M, Glickson M, et al. Failure of long-term digitali-
zation to prevent rapid ventricular response in patients with paroxysmal 
atrial fibrillation. Chest. 1991;99:1038–1040.
  35.  National Institute of Drug Abuse. The neurobiology of ecstasy. 
Slides 9–11. Available from: http://www.nida.nih.gov/pubs/teaching/
Teaching4/Teaching.html. Accessed July 29, 2011.
  36.  Black K, Shea C, Dursun S. Selective serotonin reuptake inhibitor 
discontinuation syndrome: proposed diagnostic criteria. J Psychiatry 
Neurosci. 2000;25:255–261.
  37.  Forbes. Available from: http://www.forbes.com/feeds/ap/2011/07/25/
general-health-care-us-generics-bonanza_8582330.html. Accessed July 
31, 2011.